ASXL1 and leukemia: In an NGS study from 2016 by Tefferi et al. of 182 patients with PMF, overall survival was reduced in ASXL1, SRSF2, CBL, and KIT mutated cases and leukemia-free survival was reduced in patients with mutations in SRSF2, RUNX1, CEBPA, and SH2B3. Accordingly, these observations led to the reporting of ASXL1, SRSF2, CBL, KIT, RUNX1, CEBPA, and SH2B3 as an adverse group of mutations associated with inferior OS and leukemia-free survival regardless of JAK2, CALR, or MPL mutation status [60].